Articles From: PGT Named 2014 Salute to Business Honoree to Phibro Animal Health Corporation to Host Webcast and Conference Call on December 2014 Quarterly Financial Results


N. VENICE, Fla., Oct.
Sign-up for PGT Named 2014 Salute to Business Honoree investment picks
VENICE, Fla., Oct.
Sign-up for PGT Reports 2014 Third Quarter Results investment picks
N. VENICE, Fla., Dec.
Sign-up for PGT(R) Launches Upgraded "Design Studio" on Website investment picks
2014/12/9
By Shawn Langlois, MarketWatch One exec called himself 'daddy' and offered a spanking CTPartners (CTP) shares are up 2% in after-hours trading.
Sign-up for Phallic shadows, naked scrums and a very bad day for CTPartners investment picks
U.S.-Based Registry Will Enhance Clinical Knowledge of and Explore Treatment Options for CLL Patients SUNNYVALE, Calif.
Sign-up for Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL) Patients investment picks
SUNNYVALE, Calif.
Sign-up for Pharmacyclics Named 2014 Outstanding Company by BayBio investment picks
2015/1/15
ANNAPOLIS, Md.
Sign-up for PharmAthene Awarded $195 Million Plus Post-Judgment Interest By Delaware Court Of Chancery investment picks
ANNAPOLIS, Md.
Sign-up for PharmAthene Fulfills Valortim® IDIQ Contract investment picks
2014/11/6
ANNAPOLIS, Md.
Sign-up for PharmAthene Provides Third Quarter 2014 Operational And Financial Update investment picks
PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the third quarter and nine months ended September 30, 2014.
Sign-up for PharMerica Reports Third Quarter 2014 Results investment picks
PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty home infusion, and oncology pharmacy services, today announced that David Froesel, Executive Vice President, Chief Financial Officer and Treasurer, will make a presentation regarding the Company at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona, on Tuesday, November 11, 2014, at 1:30 p.m. Mountain Time (3:30 p.m. Eastern Time). The Company also announced that a live broadcast of its conference presentation, as well as any written materials accompanying the presentation, will be available on the “For Investors” tab of the Company’s website, www.pharmerica.com , under “Webcasts and Presentations.” In addition, the webcast, transcript and written materials will be archived on the Company’s website following the event.
Sign-up for PharMerica to Present at the Credit Suisse 2014 Healthcare Conference investment picks
Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd.
Sign-up for Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest® for Prophylaxis of Hereditary Angioedema investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 (referred to as E7438 by Eisai) administered orally as a single agent in patients with advanced solid tumors and B-cell non-Hodgkin lymphomas.
Sign-up for Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor investment picks
-Trial Data Show 1404 More Sensitive Than MRI in Detecting Primary and Metastatic Prostate Cancer- TARRYTOWN, N.Y., Oct.
Sign-up for Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, administered as a single agent in patients with advanced squamous cell non-small cell lung cancer (NSCLC) who have progressed after at least two prior systemic treatments with 65% receiving three or more prior therapies (n=117). With approximately 11 months of minimum follow up, the objective response rate (ORR, the study’s primary endpoint) was 15% (95% CI = 8.7, 22.2) as assessed by an independent review committee (IRC) using RECIST 1.1 criteria and the median duration of response was not reached.
Sign-up for Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology investment picks
http://media.marketwire.com/attachments/201203/41309_medivation_logo.jpg http://media.marketwire.com/attachments/201412/82607_astellas.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164311&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA and TOKYO, JAPAN --
Sign-up for Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP investment picks
Pfizer Inc. (NYSE:PFE) announced today the publication of results from the PROFILE 1014 study in the December 4 issue of The New England Journal of Medicine .
Sign-up for Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced late-breaking data from the UNITY Trial program investigating a 12-week regimen of its all-oral daclatasvir (DCV) TRIO regimen – a fixed-dose combination of daclatasvir with asunaprevir (ASV) and beclabuvir (BCV) – in a broad range of patients with genotype 1 hepatitis C virus (HCV). The data will be presented at The Liver Meeting ® 2014, the Annual Meeting of The American Association for the Study of Liver Diseases (AASLD), in Boston, MA, November 7 – 11.
Sign-up for Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis investment picks
http://media.marketwire.com/attachments/201404/243780_Peregrine_logo_CMYK_sanspharm.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1169617&ProfileId=051205&sourceType=1 TUSTIN, CA --
Sign-up for Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium investment picks
PHH Corporation (NYSE: PHH) (“PHH” or the “Company”) today announced financial results for the quarter ended September 30, 2014.
Sign-up for PHH Corporation Announces Third Quarter 2014 Results investment picks
2014/11/7
PHI, Inc. (The Nasdaq Global Market: PHII (voting) PHIIK (non-voting)) today reported financial results for the quarter ended September 30, 2014.
Sign-up for PHI, Inc. Announces Results for the Third Quarter Ended September 30, 2014 investment picks
TEANECK, N.J., Nov.
Sign-up for Phibro Animal Health Corporation Declares Quarterly Dividend investment picks
TEANECK, N.J., Nov.
Sign-up for Phibro Animal Health Corporation Reports First Quarter investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: PGT Named 2014 Salute to Business Honoree to Phibro Animal Health Corporation to Host Webcast and Conference Call on December 2014 Quarterly Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent